Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

ACC 2022 Conference Coverage

P. Heidenreich

ACC 2023: SGLT2i Use - Dos and Don'ts

ACC 2023 Conference Coverage

A. Armbruster

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

Evidence that Obesity and Diabetes are Driven by a Diet-Induced Biol…

University of Colorado Department of Medicine

R. Johnson

Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibiti…

Cardiology Fiesta 2017

R. DeFronzo

SGLT2 Inhibitors: For Heart Failure, Diabetes, and Renal Disease

Rita Jermyn

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

Management of Heart Failure

Obafemi Awolowo University

O. A. Akinyele

Hot Topics in Heart Failure ACC.22

ACC 2022 Conference Coverage

N. Ibrahim

State-of-the-Art, Treatment of Diabetic Kidney Disease (DKD)

Primary Care Education Consortium

S. Brunton

Insulin Treatment in Patients with Type 2 Diabetes: When to Use Comb…

Emory Diabetes Education Training Academy

G. Umpierrez

Medical Management of Diastolic Dysfunction: Does The Emperor Finall…

Top Ten Topics in Clinical Cardiology 2023

S. Pinney

Important Safety Information - Off-Target Effects of New Therapies f…

Ronald Goldenberg

Current Status of Prevention and Treatment of Diabetic Nephropathy

George Bakris

Patients in Cardiometabolic Jeopardy: Evolving Strategies for Cardio…

MUSC Cardiology

D. Lloyd-Jones

Use of Finerenone in Patients with Diabetes Who Have Kidney Disease

The Texas Heart Institute

G. Bakris

What's the Ideal Therapy for Obesity?

Stanford Medicine

A. Yeoh

New Medications for Heart Failure: SGLT2 Inhibitors and Vericiguat. …

American Heart & Vascular Institute

M. Kittleson